NCT04935931View on ClinicalTrials.gov

Naltrexone Neuroimaging

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

June 15, 2022

Study Completion Date

June 30, 2022

Conditions
Eating DisordersBinge EatingPurging (Eating Disorders)
Interventions
DRUG

Naltrexone

naltrexone 50 mg PO x 1

Trial Locations (1)

64108

Children's Mercy Research Institute, Kansas City

All Listed Sponsors
collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

collaborator

University of Kansas Medical Center

OTHER

lead

Children's Mercy Hospital Kansas City

OTHER

NCT04935931 - Naltrexone Neuroimaging | Biotech Hunter | Biotech Hunter